Adjuvant screen identifies DC modifying growth factor Flt3 ligand as candidate for prostate cancer DNA vaccine

Autor:	Kirsten Malo, Ashley J. Wong, Amy H. Thorne, Laurent Humeau, Emma Masteller
Rok vydání:	2019
Předmět:	Immunology Immunology and Allergy
Zdroj:	The Journal of Immunology. 202:70.4-70.4
ISSN:	1550-6606 0022-1767
DOI:	10.4049/jimmunol.202.supp.70.4
Popis:	Prostate cancer is the most common type of cancer in men. Immunotherapies such as Sipuleucel-T have shown that stimulating the immune system to target the prostate is a viable therapeutic option. Inovio is a clinical-stage biotechnology company that uses DNA vaccines as a novel immunotherapy strategy. An advantage to plasmid DNA vaccine therapy is the ability to encode adjuvants within the vaccine in order to increase immunogenicity and efficacy. We conducted an adjuvant screen in BALB/c mice with 25 candidate plasmid encoded genetic adjuvants in combination with the prostate cancer specific tumor-associated antigen STEAP1. Antigen-specific T cell responses were measured by IFNg ELISpot. The screen revealed that the addition of a plasmid encoding dendritic cell (DC)-activating Fms-like tyrosine kinase 3 ligand (Flt3L) fused to an Fc domain, significantly increased antigen-specific T cells (p
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::306482a6bfce5e34bca58121232110ca https://doi.org/10.4049/jimmunol.202.supp.70.4 Zobrazit plný text záznamu